A decade after their team at WashU sequenced the first tumor-normal genome pair, Mardis and Wilson are bringing cancer genomics to the clinic at Nationwide Children's Hospital.
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.
Among other projects, the company will make improvements to its internal bioinformatics pipeline and develop a 5,000-sample cohort for oncology research use.
The Danish informatics firm is exploring analytical tools for its InWeb_InBioMap network, which currently contains more than 700,000 protein-protein interactions.
The company beat analyst estimates on both the top and bottom line and reported a 50 percent year over year growth in clinical testing volume in Q3.
Investigators saw muted negative selection against mutations in genomic data for more than 7,600 tumors, while mining positive selection patterns for cancer driver clues.
The firm is currently marketing its deision support analysis directly to patients and doctors while working on pilot studies with genomics providers to potentially integrate its analysis into their own reports.
A life sciences industrial strategy out this week provided long-term guidance for supporting and enhancing growth in the sector in the UK.
Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
The company said the revenue decline was expected and related to the timing of R&D projects with biopharmaceutical partners.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.